Opus Genetics (IRD) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Opus Genetics (IRD) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 133.7% versus a loss of 63.5%. Over five years, IRD leads with a +8.4% price change compared with -57.1% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($420.7 million vs $386.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | SPRY |
|---|---|---|
| Share price | $4.65 | $4.23 |
| Market cap | $386.86M | $420.66M |
| 1-day change | +4.26% | -7.24% |
| YTD return | +131.34% | -63.69% |
| 1-year return | +133.67% | -63.47% |
| 5-year return | +8.39% | -57.10% |
| EPS (TTM) | $-1.27 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.07 | $13.15 |
| 52-week low | $1.70 | $3.99 |
| Distance from 52-week high | -34.23% | -67.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +188.39% | +431.91% |
| Average volume | 2.38M | 1.86M |
| Shares outstanding | 83.20M | 99.45M |
| Employees | 27 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed SPRY by 197.1 percentage points over the past year.
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
IRD vs SPRY FAQ
Which is bigger, Opus Genetics or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $420.66M compared with $386.86M for Opus Genetics (IRD).
Which stock has performed better over the past year, IRD or SPRY?
IRD returned +133.67% over the past 12 months, compared with -63.47% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.